Hadassah

Hadassah-Developed Autoimmune Disease Drug Proves Safe in Phase I Clinical Trial

Thursday, Aug 6 2015

A drug developed at the Hadassah Medical Organization to help modulate the effects of autoimmune diseases such as rheumatoid arthritis has proven safe in a Phase I clinical trial at Hadassah. Manufactured by Protalix BioTherapeutics of Carmiel, Israel, the drug, PRX-106, proved to activate T cells, which have a central role in maintaining a well-functioning immune system.

"The results are very exciting and encouraging,” reports Prof. Yaron Ilan of Hadassah’s Internal Medicine Department A and a specialist in immunology and liver disease. “PRX-106 has the potential to be an effective agent for numerous immune-mediated disorders."

This Phase I trial tested the safety and tolerability of PRX-106 in healthy volunteers. With three separate cohorts receiving different doses of the protein compound for five consecutive days, the results demonstrated that oral administration of PRX-106 is safe and well tolerated in all three doses. In addition, researchers observed that PRX-106 triggered the action of various subsets of T cells, some of which are correlated with an anti-inflammatory response.

Preclinical studies with PRX-106 proved to alleviate both immune-mediated hepatitis and colitis in a mouse model, enhancing serum levels of regulatory T-cells and significantly improving clinical arthritis parameters, such as joint inflammation, swelling, and tissue degradation.

PRX-106 uses plant cells as a natural capsule for this protein compound. Protaliz anticipates that it will initiate the next phase of clinical trials with patients at the end of the year.

Comments

From: Gila on September 10, 2015
Would this drug also be one that could be effective in treating Crohn's Disease patients? As is now true of the RA drugs that work with T cells and the autoimmune system? Which I now inject....the oral/pill form sounds much more tolerable considering my Dr. says I will need to continue my therapy for life!
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Feb 16 2017

16 Deaf Palestinian Children Regain Hearing Thanks to Cochlear Surgery at Hadassah

A four-year-old from the Gaza Strip was born deaf and never learned to speak, but he and 15 other children from Gaza and the West Bank regained their hearing thanks to cochlear implant surgery at Hadassah Hospital Ein Kerem.

READ MORE ›
alt_text

Thursday, Feb 16 2017

Hadassah Opens Center for Disorders of Taste and Smell

As a new arm of its Unit for Oral and Maxillofacial Radiology within the Department of Oral Medicine, Hadassah Hospital Ein Kerem has opened a multidisciplinary Center for Disorders of Taste and Smell, which will focus on accurately diagnosing these conditions and facilitating follow up with the appropriate specialists.

READ MORE ›
alt_text

Monday, Feb 13 2017

Transfer with Tranquility: Holistic Help for Women with Fertility Problems

When “Naomi” first began in vitro fertility (IVF) treatment a few years ago, she expected to feel tremendous joy at the prospect of becoming pregnant; yet, all she felt was tremendous angst. “I suffered from anxiety and it was hard for me to sleep,” the Jerusalem resident said.

READ MORE ›
alt_text

Wednesday, Feb 1 2017

A Second Chance at Life, Thanks to Hadassah’s Heart Institute

A resident of a rural settlement called Dishon, established by Libyan Jewish immigrants in 1953, Eyal Amar, age 47, was rather young to suffer a devastating heart attack. Nevertheless, he did, but thanks to the courage and skill of the specialists at the Hadassah Medical Organization’s Heart Institute and their complex protocol to redesign his heavily damaged heart, Eyal is able to walk and breathe again.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More